Cautious optimism for early results of new Alzheimer’s drug

With roughly one in 10 Americans over the age of 65 living with Alzheimer’s, any progress in the effort to fight the disease would be a welcome advancement for millions of people. Experts at Mayo Clinic are “cautiously optimistic” that a new antibody known as BAN2401 will continue to show an ability to delay progression of Alzheimer’s through reduction of amyloid accumulation in the brain as it has during early phase clinical trials.

“It’s the most costly disease to our society right now,” Dr. Ronald Petersen, director of the Mayo Clinic Alzheimer’s Disease Research Center, says. “It exceeds cancer, it exceeds heart disease with regards to costs to society.”

That’s why Dr. Petersen is hopeful BAN2401 will live up to its early promise after so many other attempts at effective Alzheimer’s treatments have failed.

There is no cure for Alzheimer’s, and all currently available drugs can do is treat symptoms. But BAN2401’s purpose is to slow the progression of the disease.

More health and medical news on the Mayo Clinic News Network.

Journalists: Clean and nat sound versions of this pkg available for download at

Register (free) at


Leave a Reply

Your email address will not be published. Required fields are marked *